相关实验视频
Updated: Jan 13, 2026

09:09
In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
2.2K
在临床试验中使用人工智能来判断主要的不良心血管事件
Pablo M Marti-Castellote1, Samarra Badrouchi2, Brian Claggett2
1Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA; Cardiovascular Disease Initiative, Broad Institute of Harvard University and Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
Journal of the American College of Cardiology
|January 6, 2026
概括
人工智能 (AI) 有效地裁决主要不良心血管事件 (MACE),与医生委员会达成高度一致. 这种人工智能系统可以简化临床试验中的MACE评估,降低成本并提高可重现性.
科学领域:
- 心血管研究的心血管研究.
- 医疗人工智能的人工智能
- 临床试验方法论 临床试验方法论
背景情况:
- 主要不良心血管事件 (MACE),包括心血管死亡,心肌梗塞 (MI) 和中风,是关键的临床结果.
- 医生领导的临床事件委员会 (CEC) 在全球随机试验中对MACE的裁决是准确的,但劳动密集型.
- 人工智能 (AI) 为成本效益高,可重复的MACE裁决提供了一个潜在的解决方案.
研究的目的:
- 开发和验证基于人工智能的MACE裁决系统.
- 在一项大型全球临床试验中,将人工智能系统的性能与传统的CEC判断进行比较.
主要方法:
- 一个AI系统"Auto-MACE"是使用OpenAI的o1-mini语言模型开发的,用于MACE裁决.
- 采用临床长型模型,将AI裁决赋予信心级别.
- 在涉及5,661名患者的PARADISE-MI试验中,Auto-MACE与CEC的裁决得到了验证.
主要成果:
- 自动MACE实现了69%的死亡,46%的MI和81%的中风的自信判断.
- 自动MACE和CEC之间的一致性在自信判断方面很高 (97%的死亡,89%的中风,88%的中风).
- 所有事件的总体一致性为死亡率为86%,心脏病发作率为76%,中风率为84%,治疗效果估计类似.
结论:
- 基于人工智能的MACE裁决显示出与CEC裁决的实质性一致,特别是在心血管死亡和中风方面.
- 人工智能系统的信心水平对于高精度至关重要.
- 整合人工智能进行初步裁决,在不确定的情况下进行CEC审查,可以优化工作量并保持临床试验的准确性.
相关概念视频
Cardiovascular Drugs: Classification based on Therapeutic Indications
4.0K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.0K
Clinical Trials: Overview
4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
915
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
915
Clinical Trials
10.1K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
10.1K
Acute Coronary Syndrome III: Diagnostic Studies
207
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
207
Pharmacovigilance
1.6K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.6K

